Research Topics
Species | Charles SwantonSummaryAffiliation: Cancer Research UK Country: UK Publications
| Collaborators
|
Detail Information
Publications
Functional genomic analysis of drug sensitivity pathways to guide adjuvant strategies in breast cancerCharles Swanton
Translational Cancer Therapeutics Laboratory, Cancer Research UK London Research Institute, London, UK
Breast Cancer Res 10:214. 2008....- Integrating molecular mechanisms and clinical evidence in the management of trastuzumab resistant or refractory HER-2? metastatic breast cancerHilda Wong
Division of Hematology and Medical Oncology, Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China
Oncologist 16:1535-46. 2011..The identification of predictive biomarkers is of paramount importance to optimize health economic costs and enhance stratification of anti-HER-2 targeted therapies... - Breast cancer genome heterogeneity: a challenge to personalised medicine?Charles Swanton
Translational Cancer Therapeutics Laboratory, Cancer Research UK London Research Institute, 44 Lincoln s Inn Fields, London WC2A 3PX, UK
Breast Cancer Res 13:104. 2011.... - From genomic landscapes to personalized cancer management-is there a roadmap?Charles Swanton
Translational Cancer Therapeutics Laboratory, Cancer Research UK London Research Institute, London, United Kingdom
Ann N Y Acad Sci 1210:34-44. 2010..We argue that the failure to adopt these methods rapidly into clinical trial design will increase late stage drug attrition, waste trial resources, and risk patient harm within unselected cohorts... - Chromosomal instability, colorectal cancer and taxane resistanceCharles Swanton
Royal Marsden Hospital, Department of Medicine, London, UK
Cell Cycle 5:818-23. 2006..A phase II trial of taxanes in patients with metastatic CIN negative CRC may be indicated... - Predictive biomarker discovery through the parallel integration of clinical trial and functional genomics datasetsCharles Swanton
Cancer Research UK London Research Institute, 44 Lincoln s Inn Fields, London, WC2A 3PX, UK
Genome Med 2:53. 2010.... - Initiation of high frequency multi-drug resistance following kinase targeting by siRNAsCharles Swanton
Signal Transduction Laboratory, Cancer Research UK London Research Institute, London, UK
Cell Cycle 6:2001-4. 2007..Furthermore, this work supports efforts to identify common pathways of drug response for future drug discovery programmes... - CERT depletion predicts chemotherapy benefit and mediates cytotoxic and polyploid-specific cancer cell death through autophagy inductionAlvin J X Lee
Cancer Research UK London Research Institute, 44 Lincoln s Inn Fields, London WC2A 3LY, UK
J Pathol 226:482-94. 2012.... - Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugsCharles Swanton
Signal Transduction, Cancer Research UK London Research Institute, 44 Lincoln s Inn Fields, London WC2A 3PX, UK
Cancer Cell 11:498-512. 2007..COL4A3BP expression is increased in drug-resistant cell lines and in residual tumor following paclitaxel treatment of ovarian cancer, suggesting that it could be a target for chemotherapy-resistant cancers... - Chromosomal instability determines taxane responseCharles Swanton
Cancer Research UK, London Research Institute, London WC2A 3PX, United Kingdom
Proc Natl Acad Sci U S A 106:8671-6. 2009..Thus, pretherapeutic assessment of CIN may optimize treatment stratification and clinical trial design using these agents... - Chromosomal instability: a composite phenotype that influences sensitivity to chemotherapySarah E McClelland
Translational Cancer Therapeutics Laboratory, Cancer Research UK, London Research Institute, London, UK
Cell Cycle 8:3262-6. 2009.... - Intratumor heterogeneity and branched evolution revealed by multiregion sequencingMarco Gerlinger
Cancer Research UK London Research Institute, London, United Kingdom
N Engl J Med 366:883-92. 2012..Intratumor heterogeneity may foster tumor evolution and adaptation and hinder personalized-medicine strategies that depend on results from single tumor-biopsy samples... - A breast cancer meta-analysis of two expression measures of chromosomal instability reveals a relationship with younger age at diagnosis and high risk histopathological variablesDavid Endesfelder
Cancer Research UK London Research Institute, London, WC2A 3LY, United Kingdom
Oncotarget 2:529-37. 2011..These data support the hypothesis that chromosomal instability may be a defining feature of breast cancer biology and clinical outcome... - Relationship of extreme chromosomal instability with long-term survival in a retrospective analysis of primary breast cancerRebecca Roylance
Cancer Research UK, London Research Institute, London, United Kingdom
Cancer Epidemiol Biomarkers Prev 20:2183-94. 2011.... - Targeting chromosomal instability and tumour heterogeneity in HER2-positive breast cancerREBECCA A BURRELL
Translational Cancer Therapeutics Laboratory, London Research Institute, 44 Lincoln s Inn Fields, London WC2A 3PX, UK
J Cell Biochem 111:782-90. 2010..A greater understanding of karyotypic complexity and identification of methods to directly examine and target CIN may support novel strategies to improve outcome in cancer... - Chromosomal instability confers intrinsic multidrug resistanceAlvin J X Lee
Translational Cancer Therapeutics Laboratory, Cancer Research UK London Research Institute, London, United Kingdom
Cancer Res 71:1858-70. 2011..Our results suggest that stratifying tumor responses according to CIN status should be considered within the context of clinical trials to minimize the confounding effects of tumor CIN status on drug sensitivity... - Genetic prognostic and predictive markers in colorectal cancerAxel Walther
Department of Medicine, Royal Marsden Hospital, Downs Road, Sutton, SM2 5PT, UK
Nat Rev Cancer 9:489-99. 2009..In this Review, we attempt to summarize the sometimes confusing findings, and critically assess those markers already in the public domain... - Anti-cancer drug resistance: understanding the mechanisms through the use of integrative genomics and functional RNA interferenceDaniel S W Tan
Translational Cancer Therapeutics Laboratory, Cancer Research UK, London Research Institute, London, United Kingdom
Eur J Cancer 46:2166-77. 2010..This represents a rational approach to accelerate biomarker discovery, maximising the potential for therapeutic benefit and minimising the health economic cost of ineffective therapy... - Genome-wide RNA interference analysis of renal carcinoma survival regulators identifies MCT4 as a Warburg effect metabolic targetMarco Gerlinger
Translational Cancer Therapeutics Laboratory, Cancer Research UK London Research Institute, Lincoln s Inn Fields, London, WC2A 3LY, UK Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London, EC1M 6BQ, UK
J Pathol 227:146-56. 2012..Copyright © 2012 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd... - Unraveling the complexity of endocrine resistance in breast cancer by functional genomicsCharles Swanton
Cancer Research UK London Research Institute, Signal Transduction Laboratory, 44 Lincoln s Inn Fields, London WC2A 3PX, UK
Cancer Cell 13:83-5. 2008..CDK10 is thus a potential biomarker for sensitivity in prospective clinical trials of patients treated with endocrine therapies... - RNA interference, DNA methylation, and gene silencing: a bright future for cancer therapy?Charles Swanton
Signal Transduction Laboratory, Cancer Research UK London Research Institute, London, UK
Lancet Oncol 5:653-4. 2004 - Recent developments in treatment stratification for metastatic breast cancerSarah Barton
Breast Unit, Royal Marsden Hospital, London and Sutton, UK
Drugs 71:2099-113. 2011..The future management of MBC will increasingly focus on stratifying therapeutics based on individualized-tumour molecular aberrations... - Her2-targeted therapies in non-small cell lung cancerCharles Swanton
Cancer Research UK London Research Institute, Signal Transduction Laboratory, UK
Clin Cancer Res 12:4377s-4383s. 2006..The most promising Her2-targeted strategy will likely prove to be combinatorial approaches using an EGFR tyrosine kinase inhibitor together with Her2 dimerization inhibitors... - RNAi-mediated functional analysis of pathways influencing cancer cell drug resistanceAlvin J X Lee
Translational Cancer Therapeutics Laboratory, Cancer Research UK, London Research Institute, London, UK
Expert Rev Mol Med 11:e15. 2009..The challenge is how to integrate these data with biological samples to define relevant drug-resistant pathways in vivo... - Incidence, pattern and timing of brain metastases among patients with advanced breast cancer treated with trastuzumabThomas Yau
Breast Unit, Royal Marsden Hospital, Surrey SM2 5PT, UK
Acta Oncol 45:196-201. 2006..This study shows brain metastases are common phenomenon in HER2 positive advanced breast cancer patients receiving trastuzumab and also may implicate the brain as a sanctuary site for early relapse in this patient cohort... - Intratumor heterogeneity: seeing the wood for the treesTimothy A Yap
Department of Medicine, Royal Marsden NHS Foundation Trust, Downs Road, Sutton, Surrey SM2 5PT, UK
Sci Transl Med 4:127ps10. 2012..Envisaging tumor growth as a Darwinian tree with the trunk representing ubiquitous mutations and the branches representing heterogeneous mutations may help in drug discovery and the development of predictive biomarkers of drug response... - Epigenetic regulation in RCC: opportunities for therapeutic intervention?James Larkin
Department of Medicine, The Royal Marsden Hospital, Fulham Road, London SW3 6JJ, UK
Nat Rev Urol 9:147-55. 2012..An improved understanding of histone and chromatin regulation in RCC biology and the consequences of intratumor heterogeneity might identify novel targets in RCC and present alternative therapeutic opportunities... - Predictive molecular markers of response to epidermal growth factor receptor(EGFR) family-targeted therapiesSarah Barton
Royal Marsden Hospital, Department of Medicine, Breast Unit, Downs Road, Sutton, SM2 5PT, UK
Curr Cancer Drug Targets 10:799-812. 2010..Functional genomics elucidation of drug resistance pathways using RNA interference (RNAi) techniques may provide novel therapeutic approaches in disease resistant to EGFR pathway targeting and accelerate predictive biomarker development... - New Targets and Innovative Strategies in Cancer Treatment: one year of progress. 13-14 February 2004, Nice, FranceCharles Swanton
Royal Marsden Hospital, Fulham Road, London SW3 6JJ, UK
IDrugs 7:306-11. 2004 - Tumour heterogeneity and drug resistance: personalising cancer medicine through functional genomicsAlvin J X Lee
Translational Cancer Therapeutics, Cancer Research UK London Research Institute, UK
Biochem Pharmacol 83:1013-20. 2012.... - Optimizing treatment of metastatic renal cell carcinoma by changing mechanism of actionJames Larkin
Renal Cancer Unit, Department of Medicine, Royal Marsden Hospital, London SW3 6JJ, UK
Expert Rev Anticancer Ther 11:639-49. 2011..Ongoing research will further define the relative merits of other sequences in terms of clinical outcome... - Cell-cycle targeted therapiesCharles Swanton
Royal Marsden Hospital Breast Unit, Royal Marsden Hospital NHS Trust, London, UK
Lancet Oncol 5:27-36. 2004..This review will introduce the protein families that regulate the cell cycle, their aberrations in malignant progression and pharmacological strategies targeting this important process... - Epothilones and new analogues of the microtubule modulators in taxane-resistant diseaseMichelle Harrison
Royal Prince Alfred Hospital, Department of Medical Oncology, Missenden Road, Camperdown, Sydney 2050, Australia
Expert Opin Investig Drugs 17:523-46. 2008..Microtubule-stabilising agents typified by the epothilone class of drug have demonstrated promising activity in Phase II and III clinical trials... - The extracellular matrix protein TGFBI induces microtubule stabilization and sensitizes ovarian cancers to paclitaxelAhmed Ashour Ahmed
Functional Genomics of Drug Resistance Laboratory, Cancer Research UK Cambridge Research Institute, Li Ka Shing Centre, Robinson Way, Cambridge CB2 0RE, UK
Cancer Cell 12:514-27. 2007..These data show that ECM can mediate taxane sensitivity by modulating microtubule stability...